PerkinElmer is developing a custom bioinformatics platform for Massachusetts General Hospital as part of an effort at MGH to move a PCR-based cancer genotyping assay to a next-generation sequencing platform.

MGH researchers will use the software to analyze data for an NGS-based cancer genotyping assay it is developing for use in the research setting, though the hospital intends to move it into clinical use within the next year and a half.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.